Following swiftly on yesterday’s news, KaloBios Pharmaceuticals (Nasdaq: KBIO) announced that an investor group led by Martin Shkreli, the founder and chief executive of privately-held Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares, up from 55% previously.
KaloBios also announced the appointment of Mr Shkreli to the position of chief executive and his election as chairman of the board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the company's continued operations. KaloBios further announced that David Moradi, Tony Chase and Marek Biestek have been elected to the board of directors. In connection with 0 developments, the former directors have resigned, effective immediately.
Investment commitment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze